工程化 T 细胞及其在自身免疫性疾病中的治疗应用。
Engineered T cells and their therapeutic applications in autoimmune diseases.
机构信息
Department of Immunology and Microbiology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China.
Department of Immunology and Microbiology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China. E-mail:
出版信息
Zool Res. 2022 Mar 18;43(2):150-165. doi: 10.24272/j.issn.2095-8137.2021.363.
Chimeric antigen receptor T cells (CAR-T cells) are engineered recombinant T cells, which were initially used to treat hematopoietic malignancies and are now widely used in the treatment of various diseases. Considering their intrinsic targeting efficiency, CAR-T cells show considerable potential in the treatment of autoimmune diseases. Furthermore, regulatory T cells (Treg), a subset of CD4 T cells exhibiting immunosuppressive functions, have attracted increasing attention regarding CAR-Treg cell production. In this review, we report on recent developments in preclinical and clinical studies on CAR-T cells in autoimmune diseases and provide an outlook on opportunities and challenges of CAR-T application in such diseases.
嵌合抗原受体 T 细胞（CAR-T 细胞）是经过基因工程改造的重组 T 细胞，最初用于治疗血液系统恶性肿瘤，现在已广泛用于治疗各种疾病。鉴于其内在的靶向效率，CAR-T 细胞在自身免疫性疾病的治疗中具有很大的潜力。此外，调节性 T 细胞（Treg）是具有免疫抑制功能的 CD4 T 细胞的一个亚群，关于 CAR-Treg 细胞的产生，受到了越来越多的关注。在这篇综述中，我们报告了 CAR-T 细胞在自身免疫性疾病的临床前和临床研究中的最新进展，并对 CAR-T 在这类疾病中的应用的机遇和挑战进行了展望。
Zotero 插件